Mr. Kildani brings to Halozyme a unique perspective based on his diverse experience from both the financial and life sciences industries. Mr. Kildani joined Halozyme in November 2018 as Vice President of Investor Relations and Corporate Communications. He is responsible for developing and executing Halozyme’s investor relations strategy and serves as the primary contact for analysts and the investment community. Additionally, he oversees all aspects of corporate communications, including public relations and external and internal communications.
Prior to Halozyme, Mr. Kildani served as Vice President, Investor Relations and Business Development for Vital Therapies, Inc., where he was responsible for the overall strategy and external messaging to institutional investors and performed due diligence on potential business development opportunities. He previously held senior investor relations and corporate communications roles at Hologic, Inc. and Gen-Probe, Inc. Prior to these roles, Mr. Kildani spent over 12 years in the securities industry with a focus on life sciences companies. He was an analyst with Stark Investments, C.E. Unterberg, Towbin, and Pacific Growth Equities LLC.
Mr. Kildani received his B.S. in Business Administration from Boston College, and is a member of the National Investor Relations Institute (NIRI).